Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Eli Lilly buys global rights to MeiraGTx’s gene therapy for childhood blindness, paying $75M upfront with potential for $400M more.
Eli Lilly has acquired exclusive global rights to MeiraGTx’s AAV-AIPL1 gene therapy program, which targets Leber congenital amaurosis 4, a rare genetic eye disorder causing childhood blindness.
The deal includes an upfront $75 million payment to MeiraGTx, potential milestone payments exceeding $400 million, and royalties on future sales.
Early clinical data showed vision improvement in all 11 treated children under four born blind.
Lilly also gains access to MeiraGTx’s advanced gene therapy platforms, including novel capsids, AI-designed promoters, and a riboswitch system for controlled protein production in the eye.
The collaboration strengthens Lilly’s genetic medicine pipeline and could benefit from an FDA pilot program for faster reviews of pediatric blindness therapies.
MeiraGTx’s shares rose 15% in premarket trading.
Eli Lilly compra los derechos globales de la terapia génica de MeiraGTx para la ceguera infantil, pagando $ 75M por adelantado con potencial para $ 400M más.